Engineering Conferences International

ECI Digital Archives
Vaccine Technology VIII

Proceedings

6-12-2022

Optimization of rAd5 vectored Newcastle vaccine production in
HEK293 at high cell densities
Samia Rourou
Amani Chaaben
Alya Soudani
Meriem Ben Zakour
Omar Farnós

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Authors
Samia Rourou, Amani Chaaben, Alya Soudani, Meriem Ben Zakour, Omar Farnós, Esayas Gelaye, Martha
Yami, Amine Kamen, Khaled Trabelsi, and Héla Kallel

OPTIMIZATION OF rAd5 VECTORED NEWCASTLE VACCINE PRODUCTION IN HEK293 AT HIGH CELL
DENSITIES
Samia Rourou, Institut Pasteur de Tunis, Tunisia
samia.rourou@pasteur.tn
Amani Chaaben, Institut Pasteur de Tunis, Tunisia
Alya soudani, Institut Pasteur de Tunis, Tunisia
Meriem Ben Zakour, Institut Pasteur de Tunis, Tunisia
Omar Farnós, Department of Bioengineering, McGill University, Canada
Esayas Gelaye, National Veterinary Institute, Ethiopia
Martha Yami, National Veterinary Institute, Ethiopia
Amine Kamen, Department of Bioengineering, McGill University, Canada
Khaled Trabelsi, Institut Pasteur de Tunis, Tunisia
Héla Kallel, Institut Pasteur de Tunis, Tunisia
Key Words:

Newcastle disease, Vectored vaccine, stirred bioreactor

Newcastle disease (ND) is a highly contagious and often severe global spread syndrome that affects birds
including domestic poultry. It is caused by a virus belonging to the paramyxoviridae family.
Indeed, an outbreak of ND can be quite severe, and is considered as a constant threat to the industry and food
security worldwide. The disease can be controlled through the administration of effective vaccines.
Immunizations with inactivated or live vaccines, although protective, have some eminent disadvantages.
The aims of this work is the development of a vectored vaccine using a non-replicative human adenovirus
vector, expressing the F antigen from Newcastle Disease Virus (rAd-F-ND) in bioreactor. The recombinant
vaccine is produced using the HEK293 cell line.
HEK293 cultures were carried out in suspension, first in shake flasks and then in stirred bioreactor at 37°C, 5%
CO2 and 150 rpm in chemically defined media. The virus titers were determined by qPCR.
To improve rAd-F-ND virus productions in HEK-293 cells, we studied the effects of the following parameters in
shake flask cultures: culture media (Hycell Trans FX-H and Xell-GM), cell density, multiplicity of infection (MOI)
and feed (Xell-FS , Xell-GM and cell Boost 5).
HEK293 cells were infected at 2x106 cells/mL with rAd-F. Virus replication optimization was pursued at different
MOIs (0.1, 1, 3 and 5). The highest virus titers (5.25x1011VG/mL) were obtained with an MOI of. The specific
productivity obtained in Hycell Trans FX-H medium was very low compared to that obtained in Xell-GM medium.
When feeding was started before infection, the virus productivity improved when HEK293 cells were infected at
6x106 cells/mL. The maximum virus titer reached 1.65x1011VP/mL with feeding with Xell-FS at 3%. The specific
productivity was more pronounced under this condition. It was 2-fold higher compared to the same culture
without feed (virus titers were 2.17 1010 Vg/mL versus 6.6 108 Vg/mL).
In the current work, we also studied the rAd-F-ND virus production in HEK-293 cell line in a 7L bioreactor. Batch
and fed-batch culture modes were investigated. The cells were infected at a cell density of 5.5x106cells/mL and
the maximum virus titer was about 4x1010Vg/mL. The osmolarity level during feeding phase was maintained
under the limiting value to maximize virus productivity.
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